quercetin hydrogel

Overview

Quercetin hydrogel is a quercetin-containing hydrogel formulation designed to deliver the flavonoid quercetin in a localized, sustained, or otherwise bioavailable form. quercetin itself is a naturally occurring polyphenolic flavonoid widely found in medicinal and edible plants and is studied for a range of biological activities, including anti-inflammatory, antioxidant, barrier-protective, and anticancer effects. In hydrogel form, quercetin is incorporated into a polymeric or self-assembling matrix to improve handling, retention at the target site, and therapeutic performance.

In biomedical research, quercetin hydrogel is of interest as a drug-delivery and tissue-repair platform rather than as a single molecular target. The available recent literature links quercetin-based interventions to cancer-related signaling pathways such as Insulin-like growth factor 1 (IGF-1) and epidermal growth factor receptor (EGFR), as well as to intestinal mucosal protection and wound healing. In the specific hydrogel study context, the formulation was investigated as a self-assembling system derived from Astragalus membranaceus and was reported to accelerate diabetic wound healing, suggesting a role in regenerative medicine and local therapy.

Recent Publications Summary

Recent publications on quercetin hydrogel focused on its use as a topical therapeutic platform, particularly for wound repair. In a network pharmacology-guided study, a self-assembling quercetin hydrogel derived from Astragalus membranaceus was investigated for diabetic wound healing, with the work aiming to clarify the main active component and mechanism of action in a complex herbal context 41966023Apr. The abstract indicates that the hydrogel was designed as a topical formulation to address delayed diabetic wound healing, but the detailed mechanistic and efficacy findings are not provided in the available text 41966023Apr.

Across the broader recent literature, quercetin was also studied in several other delivery systems and disease models, underscoring its continued interest as a bioactive therapeutic agent. These included quercetin-loaded PLGA nanoparticles for oral biofilm-associated pathologies 42360515Jun, quercetin-loaded orange oil nanoemulsions for inducing apoptosis in colorectal cancer cells 42304318Jun, quercetin-loaded niosomes in atrazine-induced reproductive toxicity in rats 42332019Jun, and quercetin co-delivery with paclitaxel in integrin αvβ3-targeted solid lipid nanoparticle for triple-negative breast cancer 42267862Jun. Although these studies do not involve quercetin hydrogel, they reflect the same formulation-driven strategy of improving quercetin delivery and therapeutic performance 42360515Jun42304318Jun42332019Jun42267862Jun.

Additional publications examined quercetin’s pharmacology in cancer and inflammatory disease contexts, including gastric cancer via IGF1 signaling 42295420Jun, HBV-associated hepatocellular carcinoma via EGFR signaling 42284354Jun, osteoarthritic chondrocyte cellular senescence 42030882Apr, and hepatocellular carcinoma through ceRNA and transcription factor networks 41962406Apr. Together, these reports reinforce quercetin’s multi-target therapeutic profile, while the hydrogel-specific publication remains centered on topical diabetic wound healing and formulation-based delivery 41966023Apr42295420Jun42284354Jun42030882Apr41962406Apr.

What Changes, What Holds

1. Topical diabetic wound repair remains the main supported use, but mechanism is still not settled
REINFORCES A new hydrogel-focused report keeps the entity aligned with the Overview’s regenerative-medicine framing: quercetin hydrogel is still being developed as a localized wound-healing platform rather than as a systemic therapy. The added value is mainly confirmatory, but the available text does not supply enough mechanistic detail to strengthen the earlier claim beyond topical diabetic wound repair 41966023Apr.

2. Delivery-system innovation broadens quercetin’s formulation landscape without changing what quercetin hydrogel is
NEW DIRECTION These studies extend the broader formulation strategy around quercetin, but they do not alter the hydrogel-specific account in the Overview. They show that quercetin continues to be engineered into multiple carriers for different diseases, which supports the general idea of delivery optimization while leaving quercetin hydrogel itself unchanged as a localized hydrogel platform. The Overview covers no such role for these other vehicles 42360515Jun42304318Jun.

3. Multi-target pharmacology is reinforced, but it does not yet redefine the hydrogel formulation
REINFORCES The new cancer and inflammatory-disease papers strengthen the existing picture of quercetin as a multi-pathway bioactive compound, including links to IGF1- and EGFR-related signaling. That fits the Overview’s description of quercetin’s broad biological activity, while the hydrogel-specific claim remains limited to topical delivery and wound repair rather than a new mechanism of action for the formulation itself 42295420Jun42284354Jun.

Overview update candidates: topical quercetin hydrogel remains a wound-repair delivery platform; broader quercetin delivery and signaling studies reinforce its multi-target pharmacology but do not add hydrogel-specific claims.